insights_auto
4142 주가가 하락한 이유: 6.62%?
자세히 알아보기chevron_right
4142:TPE
Adimmune Corp
NT$14.80
arrow_downward
-6.62%(-1.05) 1D
11월 20일, 오후 1시 30분 9초 GMT+8 · TWD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto4142의 주요 통계 생성 중...
시가
NT$15.75
고가
NT$15.75
저가
NT$14.80
시가총액
63.57억
평균 거래량
112.57만
거래량
162.95만
주가수익률
85.76
52주 최고가
NT$21.50
52주 최저가
NT$14.80
EPS
NT$0.17
유통 주식수
2.35억
직원 수
564
시가
NT$15.75
고가
NT$15.75
저가
NT$14.80
시가총액
63.57억
평균 거래량
112.57만
거래량
162.95만
주가수익률
85.76
52주 최고가
NT$21.50
52주 최저가
NT$14.80
EPS
NT$0.17
유통 주식수
2.35억
직원 수
564
뉴스 기사
웹 소스 및 뉴스 파트너 제공
Bloomberg.com
·
28분 전
Stock Rout’s Spread Beyond Tech Carries Warning From Dotcom-Era
Yahoo Finance
·
1시간 전
SPDR S&P 500 ETF (SPY) Sells Apple and Microsoft on Nov. 18
Rich Picks Daily
·
18분 전
Nasdaq Composite lost 0.6% as AI-sector unease persisted despite Anthr…
프로필
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp에 관한 정보